Metoprolol Lph Labormed (Metoprolol Tartrate)

• Metoprolol, a selective β1‑adrenergic blocker, is used in several cardiovascular conditions to control heart rate and reduce cardiac workload.
• Hypertension: reduces systolic and diastolic blood pressure, decreasing risk of stroke and myocardial infarction.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion.
• Post‑myocardial infarction: improves survival by limiting adverse remodeling and preventing recurrent ischemic events.
• Chronic heart failure: enhances left‑ventricular function and reduces hospitalization rates.
• Cardiac arrhythmias: stabilizes heart rhythm by slowing conduction through the AV node.

• Metoprolol selectively antagonizes β1‑adrenergic receptors located primarily in cardiac tissue. By blocking catecholamine binding, it diminishes cyclic AMP production, leading to reduced intracellular calcium influx. The resulting decrease in heart rate (negative chronotropy), contractility (negative inotropy), and conduction velocity lowers myocardial oxygen consumption and cardiac output, thereby mitigating hypertension, ischemia, and heart‑failure progression. The drug’s β1‑selectivity limits effects on bronchial smooth muscle and peripheral vasculature, contributing to a favorable safety profile in patients without asthma.

Metoprolol may cause a range of adverse reactions, varying from mild to potentially serious.

Common Side Effects

• Fatigue: persistent tiredness or lack of energy.
• Dizziness: light‑headed sensation, especially when standing quickly.
• Bradycardia: slower than normal heart rate.
• Cold extremities: reduced blood flow to hands and feet.
• Gastrointestinal upset: nausea, abdominal discomfort or constipation.

Serious or Rare Side Effects

• Severe bradycardia: heart rate dropping below 40 bpm, requiring medical attention.
• Heart block: impaired electrical conduction leading to syncope.
• Hypotension: marked drop in blood pressure causing fainting.
• Bronchospasm: airway constriction, particularly in patients with reactive airway disease.
• Depression or mood changes: new or worsening depressive symptoms.

• Before prescribing Metoprolol, clinicians should evaluate several safety considerations to minimize risk.
• Cardiovascular assessment: review baseline heart rate and blood pressure to avoid excessive bradycardia or hypotension.
• Respiratory conditions: use cautiously in patients with asthma or chronic obstructive pulmonary disease due to possible bronchoconstriction.
• Diabetes management: monitor blood glucose, as β‑blockade may mask hypoglycaemia symptoms.
• Concomitant drugs: adjust doses when combined with other negative‑chronotropic agents or CYP2D6 inhibitors.
• Renal/hepatic impairment: consider dose reduction in moderate to severe organ dysfunction.
• Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Metoprolol can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid)

• Non‑selective β‑blockers: concurrent use may cause profound bradycardia and heart block.
• Calcium channel blockers (verapamil, diltiazem): additive negative‑inotropic and AV‑node effects.
• CYP2D6 inhibitors (paroxetine, fluoxetine): can raise metoprolol plasma concentrations, increasing toxicity risk.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents (insulin, sulfonylureas): may enhance hypoglycaemia unawareness.
• Antihypertensives (ACE inhibitors, diuretics): may cause additive blood pressure lowering.
• NSAIDs (ibuprofen, naproxen): may reduce antihypertensive efficacy.